Advertisement

Molecular Medicine

, Volume 14, Issue 11–12, pp 731–740 | Cite as

Pharmacology of Traumatic Brain Injury: Where Is the “Golden Bullet”?

  • Kathryn Beauchamp
  • Haitham Mutlak
  • Wade R. Smith
  • Esther Shohami
  • Philip F. Stahel
Review Article

Abstract

Traumatic brain injury (TBI) represents a major health care problem and a significant socioeconomic challenge worldwide. In the United States alone, approximately 1.5 million patients are affected each year, and the mortality of severe TBI remains as high as 35%–40%. These statistics underline the urgent need for efficient treatment modalities to improve posttraumatic morbidity and mortality. Despite advances in basic and clinical research as well as improved neurological intensive care in recent years, no specific pharmacological therapy for TBI is available that would improve the outcome of these patients. Understanding of the cellular and molecular mechanisms underlying the pathophysiological events after TBI has resulted in the identification of new potential therapeutic targets. Nevertheless, the extrapolation from basic research data to clinical application in TBI patients has invariably failed, and results from prospective clinical trials are disappointing. We review the published prospective clinical trials on pharmacological treatment modalities for TBI patients and outline future promising therapeutic avenues in the field.

References

  1. 1.
    Myburgh et al. (2008) Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J. Trauma 64:854–62.CrossRefGoogle Scholar
  2. 2.
    Koskinen S, Alaranta H. (2008) Traumatic brain injury in Finland 1991–2005: A nationwide register study of hospitalized and fatal TBI. Brain Inj. 22:205–14.CrossRefGoogle Scholar
  3. 3.
    Wrona RM. (2006) The use of state workers’ compensation administrative data to identify injury scenarios and quantify costs of work-related traumatic brain injuries. J. Safety Res. 37:75–81.CrossRefGoogle Scholar
  4. 4.
    Davis KL, Joshi AV, Tortella BJ, Candrilli SD. (2007) The direct economic burden of blunt and penetrating trauma in a managed care population. J. Trauma 62:622–629.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Gamboa AMJ, Holland GH, Tierney JP, Gibson DS. (2006) American Community Survey: earnings and employment for persons with traumatic brain injury. NeuroRehabilitation 21:327–33.PubMedGoogle Scholar
  6. 6.
    Woolhandler S, Himmelstein DU. (2006) Double catastrophe: injury-related bankruptcies. Med. Care 45:699–701.CrossRefGoogle Scholar
  7. 7.
    Stahel PF, Smith WR, Moore EE. (2008) Hypoxia and hypotension, the “lethal duo” in traumatic brain injury: implications for prehospital care. Intensive Care Med. 34:402–4.CrossRefGoogle Scholar
  8. 8.
    The Brain Trauma Foundation. (2007) Guidelines for the management of severe traumatic brain injury. J. Neurotrauma 24: S1–6.CrossRefGoogle Scholar
  9. 9.
    Ghallich JH FL. (1961) The use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am. Pract. Dig. Treat. 12:169–74.Google Scholar
  10. 10.
    Gobiet W. (1982) Osmotherapy and steroid therapy in acute brain edema [in German]. Schweiz Med. Wochenschr. 112:966–967.PubMedGoogle Scholar
  11. 11.
    Roberts I et al. (2004) Effect of intravenous corti-costeroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364:1321–8.CrossRefGoogle Scholar
  12. 12.
    Sauerland S, Maegele M. (2004) A CRASH landing in severe head injury. Lancet 364:1291–2.CrossRefGoogle Scholar
  13. 13.
    The Brain Trauma Foundation. (2007) Guidelines for the management of severe traumatic brain injury; XV: steroids. J. Neurotrauma 24:S91–5.CrossRefGoogle Scholar
  14. 14.
    Hall ED, Yonkers PA, McCall JM, Braughler JM. (1988) Effects of the 21-aminosteroid U74006F on experimental head injury in mice. J. Neurosurg. 68:456–61.CrossRefGoogle Scholar
  15. 15.
    Braughler JM, Pregenzer JF. (1989) The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic. Biol. Med. 7:125–30.CrossRefGoogle Scholar
  16. 16.
    Clark WM, Hazel JS, Coull BM. (1995) Lazaroids: CNS pharmacology and current research. Drugs 50:971–83.CrossRefGoogle Scholar
  17. 17.
    Hall ED, Braughler JM. (1989) Central nervous system trauma and stroke; II: physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic. Biol. Med. 6:303–13.CrossRefGoogle Scholar
  18. 18.
    Hall ED, Braughler JM. (1993) Free radicals in CNS injury. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 71:81–105.PubMedGoogle Scholar
  19. 19.
    Hall ED, McCall JM, Means ED. (1994) Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol. 28:221–68.CrossRefGoogle Scholar
  20. 20.
    Kontos HA, Povlishock JT. (1986) Oxygen radicals in brain injury. Cent. Nerv. Syst. Trauma 3:257–263.CrossRefGoogle Scholar
  21. 21.
    Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA, Ho NF. (1993) Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1:269–86.CrossRefGoogle Scholar
  22. 22.
    Marshall LF et al. (1998) Amulticenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 89:519–25.CrossRefGoogle Scholar
  23. 23.
    Roberts I. (2000) Aminosteroids for acute traumatic brain injury. Cochrane Database Syst. Rev: CD001527.Google Scholar
  24. 24.
    Behl C. (2002) Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 3:433–42.CrossRefGoogle Scholar
  25. 25.
    Roof RL, Hoffman SW, Stein DG. (1997) Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol. Chem. Neuropathol. 31:1–11.CrossRefGoogle Scholar
  26. 26.
    Asbury ET, Fritts ME, Horton JE, Isaac WL. (1998) Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav. Brain Res. 97:99–106.CrossRefGoogle Scholar
  27. 27.
    Pettus EH, Wright DW, Stein DG, Hoffman SW. (2005) Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res. 1049:112–9.CrossRefGoogle Scholar
  28. 28.
    Roof RL, Duvdevani R, Braswell L, Stein DG. (1994) Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp. Neurol. 129:64–9.CrossRefGoogle Scholar
  29. 29.
    Roof RL, Duvdevani R, Heyburn JW, Stein DG. (1996) Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp. Neurol. 138:246–51.CrossRefGoogle Scholar
  30. 30.
    Shear DA, Galani R, Hoffman SW, Stein DG. (2002) Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp. Neurol. 178:59–67.CrossRefGoogle Scholar
  31. 31.
    Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. (1999) Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 24:2134–8.CrossRefGoogle Scholar
  32. 32.
    Wright DW, Bauer ME, Hoffman SW, Stein DG. (2001) Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J. Neurotrauma 18:901–9.CrossRefGoogle Scholar
  33. 33.
    Wright DW, Ritchie JC, Mullins RE, Kellermann AL, Denson DD. (2005) Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J. Clin. Pharmacol. 45:640–8.CrossRefGoogle Scholar
  34. 34.
    Wright DW et al. (2007) ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49:391–402, 402 e391–2.CrossRefGoogle Scholar
  35. 35.
    Xiao G, Wei J, Yan W, Wang W, Lu Z. (2008) Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 12:R61.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Meldrum BS. (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 130:1007S–15S.CrossRefGoogle Scholar
  37. 37.
    Tapiero H, Mathe G, Couvreur P, Tew KD. (2002) II. Glutamine and glutamate. Biomed. Pharmacother. 56:446–57.CrossRefGoogle Scholar
  38. 38.
    Platt SR. (2007) The role of glutamate in central nervous system health and disease: a review. Vet. J. 173:278–86.CrossRefGoogle Scholar
  39. 39.
    Sayin U, Rutecki PA. (2003) Group I metabotropic glutamate receptor activation produces prolonged epileptiform neuronal synchronization and alters evoked population responses in the hippocampus. Epilepsy Res. 53:186–95.CrossRefGoogle Scholar
  40. 40.
    Birnbaumer L et al. (1994) The naming of voltage-gated calcium channels. Neuron 13:505–6.CrossRefGoogle Scholar
  41. 41.
    Levy LM, Warr O, Attwell D. (1998) Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J. Neurosci. 18:9620–8.CrossRefGoogle Scholar
  42. 42.
    Yano S, Tokumitsu H, Soderling TR. (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:584–7.CrossRefGoogle Scholar
  43. 43.
    Bullock R et al. (1998) Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89:507–18.CrossRefGoogle Scholar
  44. 44.
    Palmer AM, Marion DW, Botscheller ML, Swedlow PE, Styren SD, DeKosky ST. (1993) Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J. Neurochem. 61:2015–24.CrossRefGoogle Scholar
  45. 45.
    Yi JH, Hazell AS. (2006) Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 48:394–403.CrossRefGoogle Scholar
  46. 46.
    Chen MH, Bullock R, Graham DI, Miller JD, Mc-Culloch J. (1991) Ischemic neuronal damage after acute subdural hematoma in the rat: effects of pretreatment with a glutamate antagonist. J. Neurosurg. 74:944–50.CrossRefGoogle Scholar
  47. 47.
    Menniti F, Chenard B, Collins M, Ducat M, Shalaby I, White F. (1997) CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. 331:117–26.CrossRefGoogle Scholar
  48. 48.
    Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai SS, Frost White W. (2000) CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39:1147–55.CrossRefGoogle Scholar
  49. 49.
    Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. (1999) Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J. Neurosurg. 91:737–43.CrossRefGoogle Scholar
  50. 50.
    Chenard BL et al. (1995) (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. 38:3138–45.CrossRefGoogle Scholar
  51. 51.
    Merchant RE et al. (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. N. Y. Acad. Sci. 890:42–50.CrossRefGoogle Scholar
  52. 52.
    Yurkewicz L, Weaver J, Bullock MR, Marshall LF. (2005) The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J. Neurotrauma 22:1428–43.CrossRefGoogle Scholar
  53. 53.
    Narayan RK et al. (2002) Clinical trials in head injury. J. Neurotrauma 19:503–557.PubMedCentralCrossRefPubMedGoogle Scholar
  54. 54.
    Sanders GT, Huijgen HJ, Sanders R. (1999) Magnesium in disease: a review with special emphasis on the serum ionized magnesium. Clin. Chem. Lab. Med. 37:1011–33.PubMedGoogle Scholar
  55. 55.
    Dacey MJ. (2001) Hypomagnesemic disorders. Crit. Care Clin. 17:155–73, viii.CrossRefGoogle Scholar
  56. 56.
    Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. (2003) Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin. Chim. Acta. 334:211–15.CrossRefGoogle Scholar
  57. 57.
    Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. (2000) Hypomagnesemia and hy-pophosphatemia at admission in patients with severe head injury. Crit. Care Med. 28:2022–5.CrossRefGoogle Scholar
  58. 58.
    Vink R, McIntosh TK, Demediuk P, Weiner MW, Faden AI. (1988) Decline in intracellular free Mg2+ is associated with irreversible tissue injury after brain trauma. J. Biol. Chem. 263:757–61.PubMedGoogle Scholar
  59. 59.
    McIntosh TK, Faden AI, Yamakami I, Vink R. (1988) Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and behavioral studies. J. Neurotrauma 5:17–31.CrossRefGoogle Scholar
  60. 60.
    Saatman KE, Bareyre FM, Grady MS, McIntosh TK. (2001) Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J. Neuropathol. Exp. Neurol. 60:183–94.CrossRefGoogle Scholar
  61. 61.
    Feldman Z, Gurevitch BA, Artru AA, Oppenheim A, Shohami E, Reichenthal E, Shapira Y. (1996) Magnesium given one hour following head trauma decreases brain edema and improves neurological outcome. J. Neurosurg. 85:131–7.CrossRefGoogle Scholar
  62. 62.
    Arango MF, Mejia-Mantilla JH. (2006) Magnesium for acute traumatic brain injury. Cochrane Database Syst. Rev. CD005400.Google Scholar
  63. 63.
    Temkin NR et al. (2007) Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 6:29–38.CrossRefGoogle Scholar
  64. 64.
    Biegon A, Fry PA, Paden CMA, Tsenter J, Shohami E. (2004) Delayed Activation, rather than inhibition, of glutamate NMDA receptors improves neurological outcome after closed head injury in mice. Proc. Natl. Acad. Sci. U. S. A. 101 5117–22.PubMedCentralCrossRefPubMedGoogle Scholar
  65. 65.
    Yaka R et al. (2007) D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 21:2033–41.CrossRefGoogle Scholar
  66. 66.
    Axelrod J, Felder CC. (1998) Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem. Res. 23:575–81.CrossRefGoogle Scholar
  67. 67.
    Elphick MR, Egertova M. (2001) The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:381–408.PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Mechoulam R, Fride E, Di Marzo V. (1998) Endocannabinoids. Eur. J. Pharmacol. 359:1–18.CrossRefGoogle Scholar
  69. 69.
    Pertwee RG. (1999) Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:635–64.PubMedGoogle Scholar
  70. 70.
    Devane WA et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–9.CrossRefGoogle Scholar
  71. 71.
    Mechoulam R et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83–90.CrossRefGoogle Scholar
  72. 72.
    Hanus L et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:3662–5.PubMedCentralCrossRefPubMedGoogle Scholar
  73. 73.
    Schmid HH. (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids 108:71–87.CrossRefGoogle Scholar
  74. 74.
    Fowler CJ, Jonsson KO, Tiger G. (2001) Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 62:517–526.CrossRefGoogle Scholar
  75. 75.
    Mechoulam R, Spatz M, Shohami E. (2002) Endocannabinoids and neuroprotection. Sci. STKE 2002:RE5.PubMedGoogle Scholar
  76. 76.
    Ullrich O, Merker K, Timm J, Tauber S. (2007) Immune control by endocannabinoids—new mechanisms of neuroprotection? J. Neuroimmunol. 184:127–35.CrossRefGoogle Scholar
  77. 77.
    Feigenbaum JJ et al. (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U. S. A. 86:9584–7.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Mechoulam R et al. (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44:762–4.CrossRefGoogle Scholar
  79. 79.
    Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDAreceptor antagonist. Eur. J. Pharmacol. 283:19–29.CrossRefGoogle Scholar
  80. 80.
    Gallily R et al. (1997) Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283:918–24.PubMedGoogle Scholar
  81. 81.
    Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72:169–77.CrossRefGoogle Scholar
  82. 82.
    Chan PH. (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2–14.CrossRefGoogle Scholar
  83. 83.
    Shohami E, Ginis I, Hallenbeck JM. (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 10:119–130.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Brewster ME et al. (1997) Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. 35:361–5.PubMedGoogle Scholar
  85. 85.
    Knoller N et al. (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30:548–54.CrossRefGoogle Scholar
  86. 86.
    Maas AI et al. (2006) Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5:38–45.CrossRefGoogle Scholar
  87. 87.
    Forsyth RJ, Jayamoni B, Paine TC. (2006) Mono-aminergic agonists for acute traumatic brain injury. Cochrane Database Syst. Rev. CD003984.Google Scholar
  88. 88.
    Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK. (2006) Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr. Pharm. Des. 12:1645–80.CrossRefGoogle Scholar
  89. 89.
    Siddall OM. (2005) Use of methylphenidate in traumatic brain injury. Ann. Pharmacother. 39:1309–13.CrossRefGoogle Scholar
  90. 90.
    Husson I, Mesples B, Medja F, Leroux P, Kosofsky B, Gressens P. (2004) Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 125:163–70.CrossRefGoogle Scholar
  91. 91.
    Alban JP, Hopson MM, Ly V, Whyte J. (2004) Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Am. J. Phys. Med. Rehabil. 83:131–7; quiz 138–41, 167.CrossRefGoogle Scholar
  92. 92.
    Burke DT et al. (2003) Effects of methylpheni-date on heart rate and blood pressure among inpatients with acquired brain injury. Am. J. Phys Med. Rehabil. 82:493–7.PubMedGoogle Scholar
  93. 93.
    Moein H, Khalili HA, Keramatian K. (2006) Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin. Neurol. Neurosurg. 108:539–42.CrossRefGoogle Scholar
  94. 94.
    Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR. (2002) Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J. Neurotrauma 19:829–41.CrossRefGoogle Scholar
  95. 95.
    Buki A, Okonkwo DO, Povlishock JT. (1999) Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J. Neurotrauma 16:511–21.CrossRefGoogle Scholar
  96. 96.
    Okonkwo DO, Buki A, Siman R, Povlishock JT. (1999) Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 10:353–8.CrossRefGoogle Scholar
  97. 97.
    Okonkwo DO, Povlishock JT. (1999) An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J. Cereb. Blood Flow Metab. 19:443–451.CrossRefGoogle Scholar
  98. 98.
    Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. (2005) Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J. Neurosci. Res. 79:231–239.CrossRefGoogle Scholar
  99. 99.
    Sullivan PG, Thompson M, Scheff SW. (2000) Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp. Neurol. 161:631–7.CrossRefGoogle Scholar
  100. 100.
    Sullivan PG, Thompson MB, Scheff SW. (1999) Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp. Neurol. 160:226–34.CrossRefGoogle Scholar
  101. 101.
    Kronbach T, Fischer V, Meyer UA. (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630–5.CrossRefGoogle Scholar
  102. 102.
    Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. (2006) Cyclosporin A disposition following acute traumatic brain injury. J. Neurotrauma 23:109–16.CrossRefGoogle Scholar
  103. 103.
    Ercan M, Inci S, Kilinc K, Palaoglu S, Aypar U. (2001) Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats. Neurosurg. Rev. 24:127–30.CrossRefGoogle Scholar
  104. 104.
    Nilsson P, Hillered L, Olsson Y, Sheardown MJ, Hansen AJ. (1993) Regional changes in interstitial K+ and Ca2+ levels following cortical compression contusion trauma in rats. J. Cereb. Blood Flow Metab. 13:183–92.CrossRefGoogle Scholar
  105. 105.
    Shapira Y, Yadid G, Cotev S, Shohami E. (1989) Accumulation of calcium in the brain following head trauma. Neurol Res. 11:169–72.CrossRefGoogle Scholar
  106. 106.
    The European Study Group on Nimodipine in Severe Head Injury (1994) A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J. Neurosurg. 80:797–804.CrossRefGoogle Scholar
  107. 107.
    Bailey I et al. (1991) A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir. (Wien) 110:97–105.CrossRefGoogle Scholar
  108. 108.
    Murray GD, Teasdale GM, Schmitz H. (1996) Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials. Acta Neurochir. (Wien) 138:1163–7.CrossRefGoogle Scholar
  109. 109.
    Teasdale G et al. (1992) A randomized trial of nimodipine in severe head injury: HIT I. British/Finnish Co-operative Head Injury Trial Group. J. Neurotrauma 9Suppl 2:S545–50.PubMedGoogle Scholar
  110. 110.
    Teasdale G et al. (1990) The effect of nimodipine on outcome after head injury: a prospective randomised control trial. The British/Finnish Co-operative Head Injury Trial Group. Acta Neurochir. Suppl. (Wien) 51:315–6.Google Scholar
  111. 111.
    Langham J, Goldfrad C, Teasdale G, Shaw D, Rowan K. (2003) Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst. Rev. CD000565.Google Scholar
  112. 112.
    Ray SK, Dixon CE, Banik NL. (2002) Molecular mechanisms in the pathogenesis of traumatic brain injury. Histol. Histopathol. 17:1137–52.PubMedGoogle Scholar
  113. 113.
    Francel PC. (1992) Bradykinin and neuronal injury. J. Neurotrauma 9Suppl 1:S27–45.PubMedGoogle Scholar
  114. 114.
    Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG. (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369:744–7.CrossRefGoogle Scholar
  115. 115.
    Ellis EF, Heizer ML, Hambrecht GS, Holt SA, Stewart JM, Vavrek RJ. (1987) Inhibition of bradykinin- and kallikrein-induced cerebral arteriolar dilation by a specific bradykinin antagonist. Stroke 18:792–5.CrossRefGoogle Scholar
  116. 116.
    Bhoola KD, Figueroa CD, Worthy K. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1–80.PubMedGoogle Scholar
  117. 117.
    Kaplanski J et al. (2002) LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J. Neurotrauma 19:953–64.CrossRefGoogle Scholar
  118. 118.
    Pruneau D, Chorny I, Benkovitz V, Artru A, Roitblat L, Shapira Y. (1999) Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J. Neurotrauma 16:1057–65.CrossRefGoogle Scholar
  119. 119.
    Narotam PK et al. (1998) Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. (Wien) 140:793–802; discussion 802-3.CrossRefGoogle Scholar
  120. 120.
    Marmarou A et al. (1999) Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 16:431–44.CrossRefGoogle Scholar
  121. 121.
    Pruneau D et al. (1999) Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 43:187–94.CrossRefGoogle Scholar
  122. 122.
    Hellal O et al. (2003) Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J. Neurotrauma. 20:841–51.CrossRefGoogle Scholar
  123. 123.
    Marmarou A et al. (2005) A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J. Neurotrauma 22:1444–55.CrossRefGoogle Scholar
  124. 124.
    Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J. Neurotrauma 24:1119–31.CrossRefGoogle Scholar
  125. 125.
    Stahel PF, Smith WR, Bruchis J, Rabb CH. (2008) Peroxisome proliferator-activated receptors: “key” regulators of neuroinflammation after traumatic brain injury. PPAR Res. 2008:538141.PubMedCentralCrossRefPubMedGoogle Scholar
  126. 126.
    Hicks RR, Keeling KL, Yang MY, Smith SA, Simons AM, Kotwal GJ. (2002) Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19:705–14.CrossRefGoogle Scholar
  127. 127.
    Gong Y, Xi GH, Keep RF, Hoff JT, Hua Y. (2005) Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir. Suppl. 95:389–92.CrossRefGoogle Scholar
  128. 128.
    Leinhase I et al. (2006) Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. 199:454–64.CrossRefGoogle Scholar
  129. 129.
    Leinhase I et al. (2007) Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J. Neuroinflammation 4:13.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2008

Authors and Affiliations

  • Kathryn Beauchamp
    • 1
  • Haitham Mutlak
    • 2
    • 3
  • Wade R. Smith
    • 4
  • Esther Shohami
    • 5
  • Philip F. Stahel
    • 4
  1. 1.Division of Neurosurgery, Department of Surgery, Denver Health Medical CenterUniversity of Colorado School of MedicineDenverUSA
  2. 2.Department of Anesthesiology, University Hospital GrosshadernLudwigs Maximilian University of MunichMunichGermany
  3. 3.Department of Anesthesiology, Clinical Research and DevelopmentUniversity of Colorado Health Sciences CenterDenverUSA
  4. 4.Department of Orthopaedic Surgery, Denver Health Medical CenterUniversity of Colorado School of MedicineDenverUSA
  5. 5.Department of Pharmacology, School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations